Gedatolisib: Phase 3 success in PIK3CA-mutated cancer https://ymaho.com/gedatolisib-phase-3-success-in-pik3ca-mutated-cancer
Gedatolisib met the endpoint in the VIKTORIA-1 study, surpassing the standard of care. Learn how this will change the market. Read the detailed analysis.
In vivo gene editing: phase 3 of HAE therapy successful https://ymaho.com/in-vivo-gene-editing-phase-3-of-hae-therapy-successful
First ever successful phase 3 in vivo gene editing: lonvo-z therapy reduces HAE attacks by 87%. Learn about the breakthrough and discontinuation of prophylaxis.
iSCIB1+ DNA vaccine for melanoma: phase 3 approved by FDA https://ymaho.com/iscib1-dna-vaccine-for-melanoma-phase-3-approved-by-fda
FDA approved phase 3 trials of iSCIB1+ DNA vaccine against melanoma. Survival increase of 24%. Find out when the drug will be available and who it will help.
Biosimilar without Phase 3: FDA and EMA Rewrite the Rules https://ymaho.com/biosimilar-without-phase-3-fda-and-ema-rewrite-the-rules
FDA and EMA approved skipping Phase 3 for Herceptin biosimilar AP063. Learn how this decision will change the biosimilar market and accelerate access to cancer therapy.
Telitacicept in IgA Nephropathy: Phase 3 Results in NEJM https://ymaho.com/telitacicept-in-iga-nephropathy-phase-3-results-in-nejm
Interim Results of TELIGAN: Telitacicept Reduces Proteinuria by 58.9% vs 8.8% Placebo. Learn How the New Dual Inhibitor Is Changing the IgA Nephropathy Market.
Intellia CRISPR therapy: phase 3 data on edema — breakthrough https://ymaho.com/intellia-crispr-therapy-phase-3-data-on-edema-breakthrough
Intellia presented long-awaited phase III data of CRISPR therapy lonvo-z for hereditary angioedema: 87% reduction in attacks, 62% of patients attack-free. Learn about the breakthrough in in vivo genome editing.
CRISPR Therapy HAE: Phase 3 Data from Intellia at EAACI 2026 https://ymaho.com/crispr-therapy-hae-phase-3-data-from-intellia-at-eaaci-2026
Intellia presented the long-awaited results of phase 3 of CRISPR therapy lonvoguran ziclumeran for hereditary angioedema. Reduction of attacks by 87%, 62% of patients without therapy. Learn more.
mRNA vaccine against glioblastoma: 42% survival in phase 2 https://ymaho.com/mrna-vaccine-against-glioblastoma-42-survival-in-phase-2
Personalized mRNA vaccine showed 42% 18-month recurrence-free survival in glioblastoma. Learn details of the breakthrough JAMA study and prospects of the method.
Bayern Treble Chase: Lahm Warns Decisive Phase Begins Now https://lrivo.com/bayern-treble-chase-lahm-warns-decisive-phase-begins-now
Bayern Munich won the Bundesliga — but Philipp Lahm says the real test starts now. Can they secure a historic third treble? Here's what's at stake.
IMP761 — first LAG-3 agonist passes Phase I in autoimmune diseases https://ymaho.com/imp761-first-lag-3-agonist-passes-phase-i-in-autoimmune-diseases
Analysis of IMP761 data from Immutep at EULAR 2026: a new class of drugs for treating rheumatoid arthritis without total immunosuppression. Safety, mechanism, and prospects. Read more.